Basic Aspects of Fibrinolysis and Thrombolysis

  • H. R. Lijnen
  • D. Collen
Part of the Update in Intensive Care Medicine book series (volume 32)

Abstract

The hypothesis underlying thrombolytic therapy of thromboembolic disease is that early and sustained recanalization prevents cell death, reduces infarct size, preserves organ function, and reduces early and late mortality. Thrombolysis consists of the pharmacological dissolution of the blood clot, by intravenous infusion of plasminogen activators that activate the fibrinolytic system (Fig. 1). The fibrinolytic system includes a proenzyme, plasminogen, which is converted by plasminogen activators to the active enzyme plasmin, which in turn digests fibrin to soluble degradation products. Inhibition of the fibrinolytic system occurs by plasminogen activator inhibitors (mainly plasminogen activator inhibitor-1, PAI-1) and by plasmin inhibitors (mainly α2-antiplasmin) [1]. Thrombolytic agents that are either approved or under clinical investigation in patients with acute myocardial infarction include streptokinase, recombinant tissue-type plasminogen activator (rt-PA or alteplase), rt-PA derivatives such as reteplase and TNK-rtPA, anisoylated plasminogen-streptokinase activator complex (APSAC or anistreplase), two-chain urokinase-type plasminogen activator (tcu-PA or urokinase), recombinant single-chain u-PA (scu-PA, pro-u-PA or prourokinase), and recombinant staphylokinase and derivatives [2].
Fig. 1.

Schematic representation of the fibrinolytic system. The proenzyme plasminogen is activated to the active enzyme plasmin by tissue-type or urokinase-type plasminogen activator. Plasmin degrades fibrin into soluble fibrin degradation products. Inhibition of the fibrinolytic system may occur at the level of the plasminogen activators, by plasminogen activator inhibitors, or at the level of plasmin, mainly by α2-antiplasmin

Keywords

Lysine Methionine Thrombin Fibrinogen Triad 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Collen D, Lijnen HR (1991) Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114–3124PubMedGoogle Scholar
  2. 2.
    Collen D (1997) Thrombolytic therapy. Thromb Haemost 78:742–746PubMedGoogle Scholar
  3. 3.
    Collen D (1996) Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 93:857–865PubMedGoogle Scholar
  4. 4.
    Forsgren M, Raden B, Israelsson M, Larsson K, Heden LO (1987) Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. FEBS Lett 213:254–260PubMedCrossRefGoogle Scholar
  5. 5.
    Collen D (1980) On the regulation and control of fibrinolysis. Thromb Haemost 43:77–89PubMedGoogle Scholar
  6. 6.
    Pennica D, Holmes WE, Kohr WJ, et al. (1983) Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301:214–221PubMedCrossRefGoogle Scholar
  7. 7.
    Lijnen HR, Collen D (1991) Strategies for the improvement of thrombolytic agents. Thromb Haemost 66:88–110PubMedGoogle Scholar
  8. 8.
    Holmes WE, Pennica D, Blaber M, et al. (1985) Cloning and expression of the gene for prourokinase in Escherichia coli. Biotechnology 3:923–929CrossRefGoogle Scholar
  9. 9.
    Holmes WE, Nelles L, Lijnen HR, Collen D (1987) Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 262:1659–1664PubMedGoogle Scholar
  10. 10.
    Bangert K, Johnsen AH, Christensen U, Thorsen S (1993) Different N-terminal forms of α2-plasmin inhibitor in human plasma. Biochem J 291:623–625PubMedGoogle Scholar
  11. 11.
    Wiman B, Nilsson T, Cedergren B (1982) Studies on a form of alpha 2-antiplasmin in plasma which does not interact with the lysine-binding sites in plasminogen. Thromb Res 28:193–199PubMedCrossRefGoogle Scholar
  12. 12.
    Ichinose A, Tamaki T, Aoki N (1983) Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha2-plasmin inhibitor to fibrin. FEBS Lett 153:369–371PubMedCrossRefGoogle Scholar
  13. 13.
    Pannekoek H, Veerman H, Lambers H, et al. (1986) Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 5:2539–2544PubMedGoogle Scholar
  14. 14.
    Declerck PJ, De Mol M, Alessi MC, et al. (1988) Purification and characterization of a plasminogen activator inhibitor-1-binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263:15454–15461PubMedGoogle Scholar
  15. 15.
    Gechtman Z, Sharma R, Kreizman T, Fridkin M, Shaltiel S (1993) Synthetic peptides derived from the sequence around the plasmin cleavage site in vitronectin. Use in mapping the PAI-1 binding site. FEBS Lett 315:293–297PubMedCrossRefGoogle Scholar
  16. 16.
    Wiman B, Collen D (1979) On the mechanism of the reaction between human α2-antiplasmin and plasmin. J Biol Chem 254:9291–9297PubMedGoogle Scholar
  17. 17.
    Wiman B, Collen D (1978) On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 84:573–578PubMedCrossRefGoogle Scholar
  18. 18.
    Kruithof EKO (1988) Plasminogen activator inhibitors — a review. Enzyme 40:113–121PubMedGoogle Scholar
  19. 19.
    Thorsen S, Philips M, Selmer J, Lecander I, Astedt B (1988) Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. Eur J Biochem 175:33–39PubMedCrossRefGoogle Scholar
  20. 20.
    Chmielewska J, Ranby M, Wiman B (1988) Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for’ second site’ interactions. Biochem J 251:327–332PubMedGoogle Scholar
  21. 21.
    Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF (1989) Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 339:721–724PubMedCrossRefGoogle Scholar
  22. 22.
    Adams DS, Griffin LA, Nachajko WR, Reddy VB, Wei CM (1991) A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor. J Biol Chem 266:8476–8482PubMedGoogle Scholar
  23. 23.
    Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H (1989) Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J Clin Invest 84:647–655PubMedCrossRefGoogle Scholar
  24. 24.
    Reilly CF, Hutzelmann JE (1992) Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem 267:17128–17135PubMedGoogle Scholar
  25. 25.
    Hekman CM, Loskutoff DJ (1985) Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260:11581–11587PubMedGoogle Scholar
  26. 26.
    Declerck PJ, De Mol M, Vaughan DE, Collen D (1992) Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator. J Biol Chem 267:11693–11696PubMedGoogle Scholar
  27. 27.
    Hoylaerts M, Rijken DC, Lijnen HR, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912–2919PubMedGoogle Scholar
  28. 28.
    Thorsen S (1992) The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann NY Acad Sci 667:52–63PubMedCrossRefGoogle Scholar
  29. 29.
    McLean JW, Tomlinson JE, Kuang WJ, et al. (1987) cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 330:132–137PubMedCrossRefGoogle Scholar
  30. 30.
    Harpel PC, Gordon BR, Parker TS (1989) Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 86:3847–3851PubMedCrossRefGoogle Scholar
  31. 31.
    Fleury V, Anglès-Cano (1991) Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 30:7630–7638PubMedCrossRefGoogle Scholar
  32. 32.
    Loscalzo J, Weinfeld M, Fless GM, Scanu AM (1990). Lipoprotein (a), fibrin binding and plasminogen activation. Arteriosclerosis 10:240–245PubMedCrossRefGoogle Scholar
  33. 33.
    Edelberg JM, Gonzales-Gronow M, Pizzo SV (1990) Lipoprotein (a) inhibition of plasminogen activation by tissue-type plasminogen activator. Thromb Res 57:155–162PubMedCrossRefGoogle Scholar
  34. 34.
    Liu JN, Harpel PC, Pannell R, Gurewich V (1993) Lipoprotein (a): Akinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator. Biochemistry 32:9694–9700PubMedCrossRefGoogle Scholar
  35. 35.
    Bajzar L, Manuel R, Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270:14477–14484PubMedCrossRefGoogle Scholar
  36. 36.
    Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D (1991) Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 266:21833–21838PubMedGoogle Scholar
  37. 37.
    Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L (1997) Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 78:386–391PubMedGoogle Scholar
  38. 38.
    Collen D, Lijnen HR (1994) Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood 84:680–686PubMedGoogle Scholar
  39. 39.
    Lijnen HR, Collen D (1996) Staphylokinase, a fibrin-specific bacterial plasminogen activator. Fibrinolysis 10:119–126CrossRefGoogle Scholar
  40. 40.
    Collen D (1998) Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nature Med 4:279–284PubMedCrossRefGoogle Scholar
  41. 41.
    Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R (1984) Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 73:1731–1739PubMedCrossRefGoogle Scholar
  42. 42.
    Lijnen HR, Van Hoef B, Nelles L, Collen D (1990) Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740→Ala) and plasmin resistant scu-PA (Lys158→Glu). J Biol Chem 265:5232–5236PubMedGoogle Scholar
  43. 43.
    Husain SS (1991) Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Biochemistry 30: 5797–5805PubMedCrossRefGoogle Scholar
  44. 44.
    Liu J, Pannell R, Gurewich V (1992) A transitional state of pro-urokinase that has a higher catalytic efficiency against Glu-plasminogen than urokinase. J Biol Chem 267:15289–15292PubMedGoogle Scholar
  45. 45.
    Liu J, Gurewich V (1992) Fragment E-2 from fibrin substantially enhances pro-urokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry 31:6311–6317PubMedCrossRefGoogle Scholar
  46. 46.
    Fleury V, Gurewich V, Anglés-Cano E (1993) A study of the activation of fibrin-bound plasminogen by tissue-type plasminogen activator, single chain urokinase and sequential combinations of the activators. Fibrinolysis 7:87–96CrossRefGoogle Scholar
  47. 47.
    Fleury V, Lijnen HR, Anglés-Cano E (1993) Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem 268:18554–18559PubMedGoogle Scholar
  48. 48.
    Husain SS (1993) Fibrin affinity of urokinase-type plasminogen activator. Evidence that Zn2+ mediates strong and specific interaction of single-chain urokinase with fibrin. J Biol Chem 268:8574–8579PubMedGoogle Scholar
  49. 49.
    Declerck PJ, Lijnen HR, Verstreken M, Collen D (1991) Role of α2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma. Thromb Haemost 65:394–398PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • H. R. Lijnen
    • 1
  • D. Collen
    • 2
  1. 1.Center for Molecular and Vascular BiologyUniversity of LeuvenLeuvenBelgium
  2. 2.Center for Molecular and Vascular BiologyUniversity of LeuvenLeuvenBelgium

Personalised recommendations